ERAS
Erasca, Inc. NASDAQ Listed Jul 16, 2021$10.41
Pre-mkt
$10.33
-0.67%
Mkt Cap $3.2B
52w Low $1.06
40.3% of range
52w High $24.28
50d MA $15.52
200d MA $6.96
P/E (TTM)
-22.8x
EV/EBITDA
-8.0x
P/B
8.8x
Debt/Equity
0.1x
ROE
-38.3%
P/FCF
-11.0x
RSI (14)
—
ATR (14)
—
Beta
1.05
50d MA
$15.52
200d MA
$6.96
Avg Volume
6.3M
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
10835 Road to the Cure · San Diego, CA 92121 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12, 2026 | AMC | -0.11 | -0.10 | +9.1% | 14.65 | +3.4% | -7.0% | -7.8% | -8.8% | -7.8% | +4.2% | — |
| Nov 12, 2025 | AMC | -0.11 | -0.11 | +0.0% | 2.65 | +0.0% | -4.2% | -2.6% | +8.3% | +7.9% | +4.2% | — |
| Aug 12, 2025 | AMC | -0.12 | -0.12 | +0.0% | 1.56 | -0.6% | +3.8% | +0.6% | +5.1% | -1.9% | -2.6% | — |
| May 13, 2025 | AMC | -0.12 | -0.11 | +8.3% | 1.33 | +2.3% | -4.5% | -4.5% | -3.0% | -7.5% | -3.8% | — |
| Mar 20, 2025 | AMC | -0.12 | -0.11 | +8.3% | 1.48 | +0.0% | +3.4% | +0.7% | +0.0% | +0.0% | +4.7% | — |
| Nov 12, 2024 | AMC | -0.17 | -0.11 | +35.3% | 2.99 | +2.3% | -4.7% | -6.0% | -10.7% | -8.7% | -6.7% | — |
| Aug 12, 2024 | AMC | -0.17 | -0.29 | -70.6% | 2.59 | +4.2% | +0.4% | +0.0% | +4.6% | +8.1% | +6.2% | — |
| May 8, 2024 | AMC | -0.21 | -0.23 | -9.5% | 2.15 | -0.5% | -8.8% | -14.0% | -11.6% | -13.5% | -12.1% | — |
| Mar 27, 2024 | AMC | -0.24 | -0.20 | +16.7% | 2.06 | +17.5% | +0.0% | +4.9% | +4.4% | +5.3% | +1.5% | — |
| Nov 9, 2023 | AMC | -0.21 | -0.20 | +4.8% | 2.01 | +5.5% | +0.0% | -3.5% | +7.5% | +15.4% | +10.4% | — |
| Aug 10, 2023 | AMC | -0.27 | -0.21 | +22.2% | 2.60 | +2.3% | +11.9% | +1.2% | -2.1% | -3.8% | -3.5% | — |
| May 15, 2023 | AMC | -0.30 | -0.22 | +26.7% | 2.96 | -0.7% | -4.1% | -2.7% | -6.8% | -6.8% | -1.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 27 | Stifel | Maintains | Buy → Buy | — | $21.49 | $20.70 | -3.7% | -10.9% | -53.9% | -57.6% | -50.4% | -53.3% |
| Mar 18 | JP Morgan | Maintains | Overweight → Overweight | — | $13.36 | $13.36 | +0.0% | +1.0% | +14.2% | +9.3% | +7.2% | +9.8% |
| Mar 16 | Guggenheim | Maintains | Buy → Buy | — | $13.62 | $14.15 | +3.9% | -0.8% | -1.9% | -0.9% | +12.0% | +7.2% |
| Mar 13 | Piper Sandler | Maintains | Overweight → Overweight | — | $14.65 | $15.15 | +3.4% | -7.0% | -7.8% | -8.8% | -7.8% | +4.2% |
| Mar 13 | Mizuho | Maintains | Outperform → Outperform | — | $14.65 | $15.15 | +3.4% | -7.0% | -7.8% | -8.8% | -7.8% | +4.2% |
| Mar 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.65 | $15.15 | +3.4% | -7.0% | -7.8% | -8.8% | -7.8% | +4.2% |
| Mar 6 | Clear Street | Maintains | Buy → Buy | — | $15.54 | $15.58 | +0.3% | -0.5% | +1.4% | +0.3% | -0.3% | -5.7% |
| Jan 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.96 | $9.24 | -7.2% | -3.5% | +5.4% | +1.7% | +3.5% | +5.5% |
| Jan 16 | Piper Sandler | Maintains | Overweight → Overweight | — | $9.56 | $9.52 | -0.4% | +0.6% | +2.6% | +5.1% | +7.6% | +4.2% |
| Jan 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.23 | $6.18 | -0.8% | +20.5% | +33.4% | +53.5% | +54.4% | +57.5% |
| Dec 9 | Mizuho | Maintains | Outperform → Outperform | — | $3.34 | $3.43 | +2.7% | -1.2% | -2.4% | +1.2% | +7.8% | +2.7% |
| Nov 14 | Guggenheim | Maintains | Buy → Buy | — | $2.54 | $2.54 | +0.0% | +1.6% | +13.0% | +12.6% | +8.7% | +9.4% |
| Sep 3 | BofA Securities | Downgrade | Buy → Underperform | — | $1.60 | $1.49 | -6.9% | -10.6% | -7.5% | +0.6% | -3.1% | +0.6% |
| Aug 18 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $1.64 | $1.53 | -6.7% | -6.7% | -7.3% | -11.0% | -8.5% | -2.4% |
| Apr 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.43 | $1.39 | -2.8% | +2.1% | +4.2% | +10.5% | +1.4% | -12.6% |
| Mar 21 | Goldman Sachs | Maintains | Buy → Buy | — | $1.48 | $1.48 | +0.0% | +3.4% | +0.7% | +0.0% | +0.0% | +4.7% |
| Mar 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.48 | $1.48 | +0.0% | +3.4% | +0.7% | +0.0% | +0.0% | +4.7% |
| Jan 7 | BofA Securities | Upgrade | Neutral → Buy | — | $2.67 | $2.82 | +5.6% | +3.0% | +3.0% | -11.2% | -19.5% | -27.7% |
| Nov 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.99 | $3.06 | +2.3% | -4.7% | -6.0% | -10.7% | -8.7% | -6.7% |
| Oct 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.58 | $2.66 | +3.1% | +2.3% | +2.3% | +8.5% | +4.7% | +0.4% |
| Oct 25 | Goldman Sachs | Maintains | Buy → Buy | — | $2.58 | $2.66 | +3.1% | +2.3% | +2.3% | +8.5% | +4.7% | +0.4% |
| Aug 14 | Goldman Sachs | Maintains | Buy → Buy | — | $2.60 | $2.59 | -0.4% | -0.4% | +4.2% | +7.7% | +5.8% | +6.5% |
| Aug 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.59 | $2.70 | +4.2% | +0.4% | +0.0% | +4.6% | +8.1% | +6.2% |
| May 28 | Goldman Sachs | Maintains | Buy → Buy | — | $2.63 | $2.60 | -1.1% | -4.2% | -8.4% | -5.7% | -4.2% | -1.9% |
| May 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $1.97 | $1.87 | -5.1% | +13.7% | +19.3% | +23.9% | +31.5% | +33.5% |
| May 9 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.15 | $2.14 | -0.5% | -8.8% | -14.0% | -11.6% | -13.5% | -12.1% |
| Apr 2 | Goldman Sachs | Maintains | Buy → Buy | — | $2.16 | $2.08 | -3.7% | -0.5% | +0.5% | -3.2% | -2.8% | +3.7% |
| Mar 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.06 | $2.42 | +17.5% | +0.0% | +4.9% | +4.4% | +5.3% | +1.5% |
| Jan 5 | BofA Securities | Downgrade | Buy → Neutral | — | $2.16 | $2.07 | -4.2% | -5.6% | +0.0% | -2.3% | -3.2% | -9.7% |
| Nov 29 | Mizuho | Maintains | Buy → Buy | — | $1.99 | $2.00 | +0.8% | -9.8% | -14.4% | -15.9% | -15.4% | -11.8% |
| Nov 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $2.24 | $2.30 | +2.7% | -11.4% | -20.1% | -24.1% | -25.4% | -25.0% |
| Jun 6 | Mizuho | Maintains | Buy → Buy | — | $3.30 | $3.25 | -1.5% | -8.2% | -15.2% | -17.6% | -10.6% | -11.8% |
| Jun 6 | Evercore ISI | Maintains | Outperform → Outperform | — | $3.30 | $3.25 | -1.5% | -8.2% | -15.2% | -17.6% | -10.6% | -11.8% |
| May 16 | Goldman Sachs | Maintains | Buy → Buy | — | $2.96 | $2.94 | -0.7% | -4.1% | -2.7% | -6.8% | -6.8% | -1.4% |
| Mar 30 | Mizuho | Maintains | Buy → Buy | — | $2.96 | $3.16 | +6.8% | -2.0% | +1.7% | +6.4% | -1.4% | -0.3% |
| Feb 24 | Goldman Sachs | Maintains | Buy → Buy | — | $3.57 | $3.74 | +4.8% | +0.6% | +0.8% | +0.8% | -2.0% | -6.7% |
| Feb 3 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $4.15 | $4.49 | +8.2% | +4.8% | +2.2% | +1.4% | -3.4% | -5.1% |
| Aug 10 | JP Morgan | Maintains | Overweight → Overweight | — | $21.15 | $21.48 | +1.6% | -4.3% | -0.6% | -8.7% | -5.1% | -7.7% |
| Aug 10 | Guggenheim | Maintains | Buy → Buy | — | $21.15 | $21.48 | +1.6% | -4.3% | -0.6% | -8.7% | -5.1% | -7.7% |
| Aug 10 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $21.15 | $21.48 | +1.6% | -4.3% | -0.6% | -8.7% | -5.1% | -7.7% |
| Aug 10 | Evercore ISI | Maintains | Outperform → Outperform | — | $21.15 | $21.48 | +1.6% | -4.3% | -0.6% | -8.7% | -5.1% | -7.7% |
| Aug 10 | BofA Securities | Maintains | Buy → Buy | — | $21.15 | $21.48 | +1.6% | -4.3% | -0.6% | -8.7% | -5.1% | -7.7% |
No insider trades available.
8-K · 8.01
!! High
Erasca, Inc. -- 8-K 8.01: Material Event / Announcement
Erasca received a legal letter from Revolution Medicines alleging infringement on ERA assets, representing potential intellectual property litigation that could impact Erasca's product development pipeline and valuation.
Apr 27
8-K
Erasca, Inc. -- 8-K Filing
Erasca's KRAS inhibitor candidate demonstrated favorable pharmacokinetics with a defined active dose range of 16-32 mg daily without plateau effects, supporting advancement toward clinical development.
Apr 27
8-K · 8.01
!! High
Erasca, Inc. -- 8-K 8.01: Material Event / Announcement
This boilerplate safe harbor disclosure indicates ERAS made forward-looking statements in an 8-K filing, protecting the company from litigation if projections don't materialize, which is standard but suggests caution about recent claims made.
Apr 21
8-K
Unknown — 8-K Filing
ERA Oncology's rapidly advancing RAS-targeting pipeline with strong clinical momentum suggests meaningful near-term data catalysts that could validate its precision oncology strategy and drive stock appreciation if trials succeed.
Mar 12
Data updated apr 25, 2026 7:33am
· Source: massive.com